Vivid Cure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 4 Year, 10 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit -71.18%
(FY 2022)
- Ebitda -71.18%
(FY 2022)
- Net Worth -21.75%
(FY 2022)
- Total Assets -9.42%
(FY 2022)
About Vivid Cure Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Amit Goel and Vijay Goel serve as directors at the Company.
- CIN/LLPIN
U24299DL2020PTC374339
- Company No.
374339
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Dec 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vivid Cure Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Goel  | Director | 09-Dec-2020 | Current |
| Vijay Goel | Director | 09-Dec-2020 | Current |
Financial Performance and Corporate Structure Insights of Vivid Cure Pharmaceuticals.
Vivid Cure Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 71.18% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vivid Cure Pharmaceuticals?
In 2022, Vivid Cure Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Black Gold Enterprises Private LimitedActive 13 years 5 months
Amit Goel and Vijay Goel are mutual person
- Dykes & Dunes Enterprises Private LimitedActive 13 years 5 months
Amit Goel and Vijay Goel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vivid Cure Pharmaceuticals?
Vivid Cure Pharmaceuticals has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vivid Cure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vivid Cure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
